|Day Low/High||131.66 / 133.88|
|52 Wk Low/High||105.19 / 164.99|
The biopharmaceutical giant's top executive says the company will continue to aggressively invest in R&D and deploy capital to acquire or license assets.
Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.